First-in-Human Phase 1 Study of MORAb-202, an Antibody–Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α–Positive Advanced Solid TumorsToshio Shimizu, Noboru Yamamoto, Akihiko Shimomura et al.|Clinical Cancer Research|2021Cited by 97
Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I studyShunji Takahashi, Noboru Yamamoto, Yutaka Fujiwara et al.|Cancer Science|2021Cited by 72
Metabolomics Evaluation of Serum Markers for Cachexia and Their Intra-Day Variation in Patients with Advanced Pancreatic CancerYutaka Fujiwara, Hironobu Minami|PLoS ONE|2014Cited by 59
A Comparison of Denosumab Versus Zoledronic Acid for the Prevention of Skeletal-Related Events in Breast Cancer Patients with Bone Metastases.Alison Stopeck, Ada Braun, Roger Dansey et al.|Cancer Research|2009Cited by 21